Drug intelligence / Profile preview

CBM-901

Development stage: Unknown
Lead developer: Bridge Biotherapeutics
Modality: Small Molecules

Overview

CBM-901 is a small molecule inhibitor of the KCa3.1 (intermediate-conductance calcium-activated potassium) channel, currently under development by Cellion BioMed. KCa3.1 plays a critical role in the activation and proliferation of various immune cells, including T cells, B cells, and macrophages, as well as in the activation of fibroblasts. By inhibiting this channel, CBM-901 aims to exert anti-inflammatory and anti-fibrotic effects. The drug is primarily being investigated for the treatment of autoimmune and inflammatory conditions, with its lead program focused on Rheumatoid Arthritis, where it has reached Phase 1 clinical development.

Targets

KCNN4 (Intermediate conductance calcium-activated potassium channel protein 4)

Beyond the preview

Go deeper on CBM-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBM-901.

Explore the full profile